Mounjaro Before and After UK: What Real Results Look Like

Mounjaro (tirzepatide) has become one of the most effective weight loss medications available in the UK, and the clinical trial data supports the enthusiasm. But before looking at what results are possible, it is important to set realistic expectations. Mounjaro is not a quick fix. It works by reducing appetite and improving metabolic function, but the medication works best when combined with dietary changes and increased physical activity. The most dramatic transformations reported online tend to come from people who made significant lifestyle changes alongside taking the medication. The clinical trials measured results over 72 weeks (approximately 18 months). Most of the significant weight loss occurs in the first 9 to 12 months, with the remaining months focused on continued gradual loss and maintenance. If you are comparing yourself to social media transformations, remember that those posts typically show the very best outcomes and rarely mention the lifestyle changes that accompanied the medication.

Based on clinical trial data (SURMOUNT-1) and real-world UK user reports, here is a realistic month-by-month timeline for someone starting Mounjaro at 100kg (15 stone 10 pounds):

• Month 1 (2.5mg): 1-3kg lost. Subtle appetite reduction. Some users notice no change. This is the adjustment period.
• Month 2 (5mg): 3-5kg total lost. Appetite suppression becomes more noticeable. Food cravings start to reduce. Clothes may feel slightly looser.
• Month 3-4 (7.5mg): 6-10kg total lost. Weight loss becomes visible to others. Noticeable reduction in portion sizes. Many users report this as when the medication "really starts working."
• Month 5-6 (10mg): 10-15kg total lost. Significant visible change. Typically one to two clothing sizes smaller. Friends and family will notice.
• Month 8-10 (10-15mg): 15-20kg total lost. Major transformation. Two to three clothing sizes smaller for most people. Health markers (blood pressure, blood sugar, cholesterol) often improve significantly.
• Month 12-18 (maintenance dose): 15-22kg total lost. Rate of loss slows. Focus shifts to weight maintenance and cementing new habits.

These figures represent average outcomes. Approximately 50% of trial participants on the higher doses lost 20% or more of their body weight. Some lost considerably more; others lost less. For detailed clinical data, see our weight loss results guide.

Your starting weight significantly affects your absolute results in kilograms, though the percentage of body weight lost tends to be similar across different starting weights.

• Starting at 80kg (12 stone 8 pounds): Average loss of 12-17kg over 12-18 months. Final weight approximately 63-68kg.
• Starting at 100kg (15 stone 10 pounds): Average loss of 15-21kg. Final weight approximately 79-85kg.
• Starting at 120kg (18 stone 12 pounds): Average loss of 18-25kg. Final weight approximately 95-102kg.
• Starting at 140kg (22 stone): Average loss of 21-29kg. Final weight approximately 111-119kg.

People with a higher starting BMI tend to lose more weight in absolute terms but may not reach a "normal" BMI within the standard treatment period. This is normal and expected. Even a 10-15% reduction in body weight produces significant improvements in blood pressure, blood sugar control, joint pain, sleep quality, and cardiovascular risk factors.

Weight loss is the most visible result of Mounjaro treatment, but many UK users report equally important changes that are not reflected on the scales:

• Relationship with food: Many users describe a fundamental shift in how they think about food. The constant food noise, cravings, and preoccupation with eating that characterises many people's experience of obesity can reduce dramatically. Users frequently describe this as the most life-changing aspect of treatment.
• Energy levels: After an initial adjustment period where fatigue is common, most users report significantly improved energy levels as they lose weight and improve their metabolic health.
• Mental health: Reduced anxiety about food, improved body confidence, and better sleep can all positively affect mental wellbeing. However, some users experience mood changes, so it is important to monitor your mental health during treatment.
• Physical health markers: Blood pressure, HbA1c (blood sugar), cholesterol levels, and liver function often improve significantly, sometimes within the first few months of treatment.
• Mobility and fitness: Reduced joint pain, improved stamina, and greater ease of movement are commonly reported, particularly by those who start incorporating regular exercise as they lose weight.

Why do some people lose 25% of their body weight while others lose 10%? Several factors influence individual outcomes:

• Dietary changes: Mounjaro suppresses appetite, but the quality of food you eat still matters. Prioritising protein, vegetables, and whole foods while reducing ultra-processed foods will enhance your results. See our foods to eat and avoid guide.
• Physical activity: Even moderate exercise (brisk walking, swimming, cycling) accelerates fat loss and helps preserve muscle mass during rapid weight loss. Aim for at least 150 minutes of moderate activity per week.
• Protein intake: Adequate protein (1.2-1.6g per kg of target body weight daily) helps prevent muscle loss, which is a common concern during rapid weight loss.
• Dose adherence: Taking your injection consistently on the same day each week maximises effectiveness. Missing doses or irregular timing reduces results.
• Dose achieved: Higher doses generally produce greater weight loss. Not everyone tolerates the maximum 15mg dose, and that is fine. Your prescriber will find the right balance between effectiveness and side effects.
• Genetics and metabolism: Individual biology plays a role. Some people are simply stronger responders to GLP-1/GIP receptor agonists than others.

An important consideration when evaluating Mounjaro results is what happens after treatment ends. Research shows that most people regain some weight after stopping GLP-1 medications. In the SURMOUNT-4 trial, participants who switched from tirzepatide to placebo after 36 weeks regained approximately half of the weight they had lost over the following year. This does not mean treatment is pointless. The key findings are:

• People who made lasting lifestyle changes (diet and exercise habits) during treatment retained more of their weight loss
• Some weight regain is biological, not a failure of willpower. The body's hunger and metabolism systems adjust when weight is lost rapidly
• Many prescribers now recommend long-term or indefinite treatment at a reduced maintenance dose rather than stopping entirely
• Even partial weight regain still leaves most people significantly lighter and healthier than before treatment

For a more detailed look at long-term outcomes, see our long-term use guide. And to find the most affordable pharmacy for ongoing treatment, use our price comparison tool.